As immunotherapy expands beyond cancer into autoimmune, neurological, and rare diseases, the demand for plasma-derived therapies is rising at an unprecedented pace. This growing clinical reliance is also reshaping the business landscape. The blood plasma market is projected to reach approximately US$33.5 billion in 2026 and grow to nearly US$54.2 billion by 2033, registering a CAGR of 7.1% in the forecast period. Behind these numbers lies a key factor of scientific innovation, increasing patient dependence on plasma-derived medicines, and the growing challenge of ensuring a sustainable plasma supply to meet rising global healthcare demands.
Why Immunoglobulins Have Become Non-Negotiable in Immune Care
Every plasma-derived therapy begins long before it reaches a patient. Behind each treatment is a complex process of plasma collection, protein separation, and advanced manufacturing that transforms donated plasma into life-saving medicines. Among the proteins extracted from plasma, immunoglobulins have become one of the most valuable. Rich in antibodies, they are now a frontline therapy for immune deficiencies, autoimmune disorders, and several neurological conditions, helping patients manage diseases that often require lifelong treatment.
As the use of immunoglobulin therapies continues to expand, demand for high-quality plasma has grown alongside it. This increasing clinical reliance has made immunoglobulins the largest revenue-generating product segment. It has also fueled investments in the plasma fractionation market, where plasma is separated into specialized proteins through advanced purification processes before being developed into life-saving therapies.
The Technology Behind Every Plasma Donation
As demand for plasma-derived therapies continues to grow, expanding plasma collection has become just as important as developing new treatments. Every vial of immunoglobulin begins with a donor, making collection efficiency a critical factor in ensuring a stable supply. Today, advances in plasmapheresis technology are helping donation centers collect more plasma safely and comfortably, allowing manufacturers to produce more life-saving therapies from the same donor base.
A notable example came between May and December 2025, when Takeda's BioLife plasma centers introduced Fresenius Kabi's Adaptive Nomogram technology on the Aurora Xi Plasmapheresis System. The FDA-reviewed technology personalized each donor's collection cycle, increasing plasma volume per donation by approximately 11.5%. While improving collection is one part of the equation, maintaining plasma quality throughout storage and transportation is equally essential. This is where the disposable blood bags market plays a vital supporting role, while the additional plasma collected ultimately feeds into the plasma fractionation market, ensuring a more resilient supply chain for plasma-derived therapies.
Patient-Centric Innovation is Transforming Plasma Therapies
As plasma collection and fractionation continue to strengthen the supply chain, the greatest impact is being felt by patients. For many living with rare diseases, plasma-derived therapies remain the most effective and sometimes the only treatment option. Conditions such as hereditary angioedema, hemophilia, and primary immunodeficiency require long-term care, making continued innovation essential to improving both access and treatment outcomes.
Recent developments reflect this shift. In July 2024, Biotest AG partnered with Kedrion to introduce its FDA-approved immunoglobulin therapy Yimmugo to the U.S. market, expanding treatment options for patients with primary immunodeficiency. Innovation is also focused on improving the treatment experience. In October 2025, Takeda launched its HyHub and HyHub Duo devices for use with HYQVIA, simplifying at-home infusion preparation and giving patients greater flexibility in managing long-term therapy.
New Markets Are Bolstering the Next Growth Phase
The journey of plasma doesn't end once a life-saving therapy is produced. Advances in fractionation are enabling processors to utilize more plasma components than ever before, ensuring that each donation delivers greater clinical and commercial value. Even by-products generated during processing are finding new applications, contributing to industries tracked in the plasma feed market and highlighting how innovation is maximizing the potential of every plasma donation.
Demand is also shifting geographically, and not just by application. Asia Pacific is emerging as the fastest-growing region. It is attributed to expanding fractionation facilities, superior healthcare infrastructure, and improved diagnosis rates across countries such as China and India. North America continues to lead with its well-established donation and fractionation infrastructure. What was once a concept dominated by a handful of Western markets, is slowly becoming a genuinely global one, with new demand centers adding pressure to an already tight supply chain.
The Future Depends on a Sustainable Plasma Supply
The future of plasma-derived medicine is no longer defined by scientific possibility but by the ability to meet growing demand. As more patients rely on plasma-based therapies for immune, neurological, and rare diseases, manufacturers are focusing on expanding plasma collection, increasing fractionation capacity, and improving treatment accessibility. In the years ahead, every plasma donation will likely carry even greater significance, not only supporting life-saving therapies but also shaping the future of modern healthcare.
